Migraine Drug Could Add 10% to Amgen's Revenue

Posted in Biotech

May 21, 2018 • 2 min read

On CNBC's "Power Lunch," a Wall Street analyst stated that Amgen's recently approved migraine drug, Aimovig, could become a $2 billion business in the next five years. That revenue would equate to a 10 percent increase to Amgen's revenue as the drug provides a huge unmet need for adults who deal with migraines. ...

Allergan making strong market development push with CoolSculpting

Posted in Biotech

May 17, 2018 • 4 min read

Allergan is taking advantage of the popularity of CoolSculpting, the procedure they acquired from ZELTIQ, by launching a DTC marketing campaign. CoolSculpting revenue has continued strong growth in recent quarters and helped offset declines in other Allergan product categories....

Novartis sacrifices its top attorney in an attempt to quell clamor over $1.2M in Cohen payments — while ex-CEO Jimenez struggles to explain

Posted in Biotech

May 17, 2018

Never in my dreams did I think I would be writing a story that tied in a porn actress, the president of the US, a Russian oligarch and Novartis payments.

Posted in Biotech

May 09, 2018

Valeant to become Bausch Health Companies in rebrand

Posted in Biotech

May 08, 2018

Takeda Buys Shire For $62 Billion Creating Pharma Giant

Posted in Biotech

May 08, 2018